Merus (NASDAQ:MRUS) Earns Overweight Rating from Analysts at Piper Sandler

Piper Sandler assumed coverage on shares of Merus (NASDAQ:MRUS) in a research report report published on Thursday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $84.00 target price on the biotechnology company’s stock.

A number of other analysts also recently issued reports on the stock. UBS Group initiated coverage on shares of Merus in a report on Thursday, October 24th. They set a “buy” rating and a $72.00 price target on the stock. Citigroup lifted their price target on Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Guggenheim reiterated a “buy” rating on shares of Merus in a research report on Wednesday. Wells Fargo & Company began coverage on Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $85.00 target price on shares of Merus in a research note on Monday, December 2nd. One analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $85.92.

Merus Trading Down 0.2 %

Shares of NASDAQ:MRUS opened at $40.20 on Thursday. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The business has a 50 day moving average of $41.55 and a two-hundred day moving average of $47.17. The company has a market capitalization of $2.75 billion, a PE ratio of -10.18 and a beta of 1.11.

Institutional Trading of Merus

A number of hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its holdings in shares of Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 300 shares during the period. Avior Wealth Management LLC acquired a new stake in shares of Merus in the 4th quarter worth $76,000. nVerses Capital LLC boosted its holdings in shares of Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,500 shares in the last quarter. US Bancorp DE acquired a new position in shares of Merus during the third quarter worth about $103,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 489 shares during the period. 96.14% of the stock is owned by institutional investors and hedge funds.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.